Innova Captab Ltd Stock Price Today (NSE: INNOVACAP)
Fundamental Score
Innova Captab Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Innova Captab Ltd share price today is ₹934.90, down 3.04% on NSE/BSE as of 17 June 2026. Innova Captab Ltd (INNOVACAP) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.09K (Cr). The 52-week high for INNOVACAP share price is ₹954.00 and the 52-week low is ₹622.00. At a P/E ratio of 32.89x, INNOVACAP is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 14.34% and a debt-to-equity ratio of 0.33.
Innova Captab Ltd Share Price Chart — NSE/BSE Historical Performance
Innova Captab Ltd share price chart: 17.85% return over the past month. 52-week high ₹954.00, 52-week low ₹622.00.
Innova Captab Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹862.80 | ₹880.00 | ₹836.80 | ₹862.40 | 35.65K (Cr) | |
| ₹855.00 | ₹880.00 | ₹851.35 | ₹860.80 | 33.86K (Cr) | |
| ₹846.20 | ₹864.90 | ₹837.05 | ₹850.40 | 36.59K (Cr) | |
| ₹845.00 | ₹870.00 | ₹841.00 | ₹846.20 | 41.57K (Cr) | |
| ₹858.70 | ₹864.45 | ₹834.50 | ₹843.50 | 28.61K (Cr) | |
| ₹844.15 | ₹882.00 | ₹834.00 | ₹855.05 | 85.59K (Cr) | |
| ₹868.50 | ₹891.50 | ₹841.20 | ₹848.30 | 33.51K (Cr) | |
| ₹894.70 | ₹894.70 | ₹867.00 | ₹872.25 | 33.12K (Cr) | |
| ₹873.30 | ₹904.00 | ₹865.40 | ₹880.20 | 48.89K (Cr) | |
| ₹885.00 | ₹905.95 | ₹869.00 | ₹873.30 | 46.59K (Cr) |
Innova Captab Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹855.00 | ₹880.00 | ₹836.80 | ₹862.40 | +0.87% | |
| ₹790.00 | ₹918.00 | ₹790.00 | ₹850.40 | +7.65% | |
| ₹685.00 | ₹763.40 | ₹670.00 | ₹752.05 | +9.79% | |
| ₹623.00 | ₹729.00 | ₹622.00 | ₹689.85 | +10.73% | |
| ₹694.90 | ₹737.00 | ₹659.55 | ₹668.25 | -3.84% | |
| ₹720.10 | ₹764.95 | ₹624.00 | ₹695.20 | -3.46% | |
| ₹725.00 | ₹776.90 | ₹660.00 | ₹720.10 | -0.68% | |
| ₹822.40 | ₹834.00 | ₹702.95 | ₹718.25 | -12.66% | |
| ₹860.00 | ₹881.00 | ₹792.90 | ₹831.10 | -3.36% | |
| ₹901.00 | ₹944.00 | ₹816.60 | ₹853.00 | -5.33% | |
| ₹912.60 | ₹954.00 | ₹870.60 | ₹902.05 | -1.16% | |
| ₹862.75 | ₹939.00 | ₹821.65 | ₹909.35 | +5.40% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Innova Captab Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Innova Captab Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INNOVACAP across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Revenue Growth (19.54%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (27.21% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (35.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (16.92x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (50.90%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-15.23%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-37.35% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-258.21 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Innova Captab Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Innova Captab Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Innova Captab LtdInnova Captab L...Selected✓ INNOVACAP • 544067 | 53.3/100 | ₹934.90₹935 | ₹4093.03₹4093.03 | 32.89Average 32.9 Average | 14.34%Average 14.34% Average | 14.63%Average 14.63% Average | 0.33Excellent 0.3 Excellent | 35.71%Excellent 35.71% Excellent | 27.21%Excellent 27.21% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Innova Captab Ltd PE Ratio History
Historical price-to-earnings ratio for INNOVACAP — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹22.41 | ₹720.10 | 32.1x |
| FY 2024 | ₹18.66 | ₹1115.40 | 59.8x |
| FY 2023 | ₹11.87 | ₹541.40 | 45.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Innova Captab Ltd Quarterly Performance
Latest quarterly metrics for INNOVACAP — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.54%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-15.23%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
27.21%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
35.71%
Compounded annual net profit growth over 5 years
Innova Captab Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INNOVACAP — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Innova Captab Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Innova Captab Ltd (INNOVACAP) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Innova Captab Ltd
About INNOVACAP (Innova Captab Ltd)
Innova Captab Ltd is a dynamic pharmaceutical entity with a broad spectrum of capabilities, ranging from advanced research and development to efficient manufacturing and widespread... distribution. Their core strength lies in providing comprehensive contract development and manufacturing organization (CDMO) services to domestic pharmaceutical giants, facilitating the production of diverse drug formulations. This positions them as a crucial partner in the pharmaceutical supply chain, contributing significantly to the availability and accessibility of essential medications. Innova Captab's operational framework is designed to meet the evolving demands of the pharmaceutical landscape, enabling them to adapt to market dynamics and regulatory changes effectively. Beyond their CDMO services, Innova Captab also specializes in developing and marketing a robust portfolio of generic formulations. These products encompass a wide range of therapeutic areas, catering to prevalent health needs. Their generic drug offerings include crucial medications such as cephalosporins, targeting bacterial infections, and proton pump inhibitors (PPIs) for managing gastric conditions. Additionally, their product line extends to anticholinergics and heparin-based medications, along with NSAIDs, analgesics, and antipyretics for pain and fever management. The inclusion of anticold and antiallergic drugs further highlights their commitment to providing comprehensive healthcare solutions. Innova Captab's commitment to quality and innovation is evident in their end-to-end approach, from drug conception to commercialization. By integrating research, development, manufacturing, and distribution under one umbrella, they ensure stringent quality control and efficient operational processes. This integrated model, coupled with their expanding portfolio of generic formulations and robust CDMO services, positions Innova Captab as a key player in the pharmaceutical sector, both within India and in the global arena. They aim to continue growing and adding value to the broader healthcare ecosystem.
Company Details
Key Leadership
INNOVACAP Share Price: Frequently Asked Questions
What is the current share price of Innova Captab Ltd?
Innova Captab Ltd (INNOVACAP) trades at ₹934.90 on NSE and BSE. Market cap ₹4.09K (Cr). Educational data only.
What is the P/E ratio of Innova Captab Ltd?
Innova Captab Ltd has a P/E of 32.89x vs industry average 31.77x.
What is the Bull Run score for Innova Captab Ltd?
Innova Captab Ltd has a Bull Run score of 53.3/100 based on 25+ financial parameters.
Does Innova Captab Ltd pay dividends?
Innova Captab Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Innova Captab Ltd?
Innova Captab Ltd has ROE of 14.34%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Innova Captab Ltd?
Innova Captab Ltd has debt-to-equity of 0.33.
Is Innova Captab Ltd a good investment?
Bull Run gives Innova Captab Ltd a score of 53.3/100. This is not investment advice — consult a SEBI-registered advisor.